Prunin

Prunin

SCHEMBL2532187

O=C1CC(c2ccc(O)cc2)Oc2cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLCO2B1 O94956 4/20 1.00
PTPN1 P18031 3/20 1.00
SYNJ2 O15056 1/20 0.86
KDM1A O60341 2/20 0.79
CYP19A1 P11511 4/20 0.79
GSK3B P49841 3/20 0.79
UBE2N P61088 1/20 0.79
TRPA1 O75762 1/20 0.70
P4HB P07237 1/20 0.70
TRPV1 Q8NER1 1/20 0.70
PKM P14618 1/20 0.69
XDH P47989 1/20 0.68
DPP4 P27487 2/20 0.65
TDP1 Q9NUW8 3/20 0.62
CALM1 P0DP23 2/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
POLB P06746 1/20 0.62
CACNA1B Q00975 1/20 0.62
APBA1 Q02410 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Prunin SCHEMBL13904742 1.00 SLCO2B1 (1.00) SLCO2B1PTPN1SYNJ2KDM1ACYP19A1
Prunin SCHEMBL29560212 1.00 SLCO2B1 (1.00) SLCO2B1PTPN1SYNJ2KDM1ACYP19A1
Prunin SCHEMBL31233345 1.00 SLCO2B1 (1.00) SLCO2B1PTPN1SYNJ2KDM1ACYP19A1
Prunin SCHEMBL29336352 1.00 SLCO2B1 (1.00) SLCO2B1PTPN1SYNJ2KDM1ACYP19A1
Prunin SCHEMBL318230 1.00 SLCO2B1 (1.00) SLCO2B1PTPN1SYNJ2KDM1ACYP19A1
Prunin SCHEMBL1122487 1.00 SLCO2B1 (1.00) SLCO2B1PTPN1SYNJ2KDM1ACYP19A1
Prunin SCHEMBL13625098 1.00 SLCO2B1 (1.00) SLCO2B1PTPN1SYNJ2KDM1ACYP19A1
Prunin SCHEMBL31233342 1.00 SLCO2B1 (1.00) SLCO2B1PTPN1SYNJ2KDM1ACYP19A1
Prunin SCHEMBL318229 1.00 SLCO2B1 (1.00) SLCO2B1PTPN1SYNJ2KDM1ACYP19A1
SCHEMBL29822818 0.93 PTPN1 (0.88) SLCO2B1PTPN1SYNJ2KDM1ACYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230172901-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS GRETALS AUSTRALIA PTY LTD (AU) 2023-06-08 US claimed
EP-4146194-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS Gretals Australia Pty Ltd (AU) 2023-03-15 EP claimed
WO-2021222987-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS GRETALS AUSTRALIA PTY LTD (AU) 2021-11-11 WO claimed
US-20210205344-A1 COMPOSITION CONTAINING FLAVONOID-CYCLODEXTRIN CLATHRATE COMPOUND TAIYO KAGAKU CO., LTD. (JP) 2021-07-08 US claimed
EP-3805399-A1 COMPOSITION CONTAINING FLAVONOID-CYCLODEXTRIN CLATHRATE COMPOUND Taiyo Kagaku Co., Ltd. (JP) 2021-04-14 EP claimed
CN-112236525-A Compositions containing flavonoid-cyclodextrin inclusion compounds 太阳化学株式会社 2021-01-15 CN claimed
EP-3733860-A1 FLAVONOID INCLUSION COMPOUNDS Taiyo Kagaku Co., Ltd. (JP) 2020-11-04 EP claimed
US-10676496-B2 Method for producing flavonoid inclusion compound TAIYO KAGAKU CO., LTD. (JP) 2020-06-09 US claimed
EP-3453766-B1 METHOD FOR PRODUCING FLAVONOID INCLUSION COMPOUNDS TAIYO KAGAKU KK (JP) 2020-06-03 EP claimed
US-20200062796-A1 METHOD FOR PRODUCING FLAVONOID INCLUSION COMPOUND TAIYO KAGAKU CO., LTD. (JP) 2020-02-27 US claimed
CN-110462052-A Process for producing flavone inclusion compound TAIYO KAGAKU KK 2019-11-15 CN claimed
US-20190248825-A1 METHOD FOR PRODUCING FLAVONOID INCLUSION COMPOUND TAIYO KAGAKU CO., LTD. (JP) 2019-08-15 US claimed
EP-3453766-A1 METHOD FOR PRODUCING FLAVONOID CLATHRATE Taiyo Kagaku Co., Ltd. (JP) 2019-03-13 EP claimed
CN-103230408-B Method for preparing phloretin FOSHAN JINJUNKANG HEALTH SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2014-10-22 CN claimed
CN-103230408-A Method for preparing phloretin FOSHAN JINJUNKANG HEALTH SCIENCE AND TECHNOLOGY CO LTD 2013-08-07 CN claimed
US-20090253616-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2009-10-08 US claimed
EP-2026808-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER AstraZeneca AB (SE) 2009-02-25 EP claimed
WO-2007132215-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2007-11-22 WO claimed
EP-0314959-B1 SELECTIVE HYDROLYSIS SOCIETE DES PRODUITS NESTLE S.A. (CH) 1992-05-27 EP claimed
EP-0314959-A1 Selective hydrolysis SOCIETE DES PRODUITS NESTLE S.A. (CH) 1989-05-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248825-A1 METHOD FOR PRODUCING FLAVONOID INCLUSION COMPOUND MGAM, SI, MANBA SLCO2B1 2397/4885PTPN1 2973/4885SYNJ2 1630/4885
US-20090253616-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER AURKC, AURKB, AURKA SLCO2B1 64/4885PTPN1 2673/4885SYNJ2 2445/4885
US-10676496-B2 Method for producing flavonoid inclusion compound MGAM, SI, MANBA SLCO2B1 2397/4885PTPN1 2973/4885SYNJ2 1630/4885
US-20200062796-A1 METHOD FOR PRODUCING FLAVONOID INCLUSION COMPOUND MGAM, SI, MANBA SLCO2B1 2397/4885PTPN1 2973/4885SYNJ2 1630/4885
US-20230172901-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS MMP1, COL1A1, SERPINB1 SLCO2B1 3287/4885PTPN1 2926/4885SYNJ2 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.